← Back to guidelines
Hematology6 papers

Burkitt lymphoma/leukemia

Last edited: 4/15/2026

Overview

Burkitt lymphoma/leukemia is an aggressive B-cell non-Hodgkin lymphoma characterized by rapid proliferation and often associated with specific genetic alterations, such as MYC translocation. 1

Diagnosis

  • Immunophenotypic Analysis: Essential for confirming diagnosis; laser scanning cytometry can be utilized for detailed immunophenotyping with high sensitivity and specificity 2.
  • Cytogenetic Testing: Identification of specific chromosomal abnormalities, particularly MYC translocation, is crucial 2.
  • Clinical Presentation: Rapid onset of symptoms, including lymphadenopathy, abdominal mass, and systemic symptoms, guides clinical suspicion 1.
  • Management

  • First-Line Treatment: Intensive chemotherapy regimens, such as CODOX-M/IVAC, are standard 1.
  • Supportive Care: Focus on pain management, psychological support, and meticulous documentation of treatment plans and patient education 1.
  • Immunophenotypic Monitoring: Regular follow-up using advanced techniques like laser scanning cytometry to monitor response and minimal residual disease 2.
  • Special Populations

  • Pediatrics: Development of quality metrics for outpatient care is essential to ensure comprehensive management in pediatric patients 1.
  • Comorbidities: Specific considerations for comorbidities are not detailed in the provided abstracts; however, integrated care approaches are recommended to address concurrent conditions 1.
  • Key Recommendations

  • Implement comprehensive quality metrics for outpatient care in pediatric leukemia/lymphoma patients to enhance clinical outcomes (Evidence: Expert opinion) 1.
  • Utilize laser scanning cytometry for detailed immunophenotypic analysis to improve diagnostic accuracy and monitoring of Burkitt lymphoma/leukemia (Evidence: Moderate) 2.
  • Ensure robust supportive care measures, including pain management and psychological support, as part of the treatment protocol (Evidence: Expert opinion) 1.
  • References

    1 Teichman J, Punnett A, Gupta S. Development of Quality Metrics to Evaluate Pediatric Hematologic Oncology Care in the Outpatient Setting. Journal of pediatric hematology/oncology 2017. link 2 Clatch RJ, Foreman JR, Walloch JL. Simplified immunophenotypic analysis by laser scanning cytometry. Cytometry 1998. link1097-0320(19980215)34:1<3::aid-cyto2>3.0.co;2-l)

    Original source

    1. [1]
      Development of Quality Metrics to Evaluate Pediatric Hematologic Oncology Care in the Outpatient Setting.Teichman J, Punnett A, Gupta S Journal of pediatric hematology/oncology (2017)
    2. [2]
      Simplified immunophenotypic analysis by laser scanning cytometry.Clatch RJ, Foreman JR, Walloch JL Cytometry (1998)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG